Multiple endocrine neoplasia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Multiple endocrine neoplasia Classification and external resources | |
| ICD-10 | D44.8 |
|---|---|
| MeSH | D009377 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Multiple endocrine neoplasia (MEN) (or "multiple endocrine adenomas", or "multiple endocrine adenomatosis" -- "MEA") consists of three syndromes featuring tumors of endocrine glands, each with its own characteristic pattern. The presence of any one tumor type does not automatically have a patient labelled as MEN, but a search of the other at-risk areas is usually undertaken, especially when there are suggestive clinical signs.
MEN syndromes are inherited as autosomal dominant disorders. Medullary carcinoma of the thyroid may occur as an autosomal dominant in the absence of other features.
Comparison
| Feature | MEN 1 | MEN 2 | ||
|---|---|---|---|---|
| MEN 2A | MEN 2B | FMTC | ||
| Eponym | Wermer syndrome | Sipple syndrome | (see below) | (none) |
| OMIM | 131100 | 171400 | 162300 | 155240 |
| Pancreatic tumors | insulinoma, gastrinoma | - | - | - |
| Pituitary adenoma | Yes | - | - | - |
| Parathyroid hyperplasia | Yes | Yes | - | - |
| Medullary thyroid carcinoma | - | Yes | 100% | 100% |
| Pheochromocytoma | - | Yes | 50% | - |
| Marfanoid body habitus | - | - | 80% | - |
| Multiple Mucosal Neuromata | - | - | >95% | - |
| Spontaneous mutation rate | 50% | |||
| Gene(s) | MEN1 (131100) | RET (164761) | RET (164761) | RET (164761), NTRK1 (191315) |
| Approx. prevalence | 1 in 1,000,000 | |||
| Initial description (year) | 1954[1] | 1961[1] | 1965 | |
(Blanks indicate that data are not yet available.)
MEN 2B was known as MEN 3 for a short time in the 1970s, but that term is no longer used. Although a variety of eponyms have been proposed for MEN2B (e.g. Williams-Pollock syndrome, Gorlin-Vickers syndrome, and Wagenmann-Froboese syndrome), none ever gained suffiicient traction to merit continued use and, indeed, are all but abandoned in the medical literature. Another early report was Schimke et al in 1968.[1]
OMIM also includes a fourth form of multiple endocrine neoplasia ("MEN4"), associated with CDKN1B.[1] The presentation is believed to overlap that of MEN1 and MEN2.[1]
MEN type 1
Type 1 is also known as Wermer's syndrome after Dr Paul Wermer, who described it in 1954:[1]
- Parathyroid hyperplasia/tumour causing hyperparathyroidism.
- Pancreatic islet cell tumours causing hypoglycaemia (insulinoma) and Zollinger-Ellison syndrome (gastrinoma).
- Pituitary adenoma which may cause pituitary hormone excess.
The causative mutation is in the MEN1 gene at 11q13 which encodes a nuclear protein called menin that is believed to act as a tumor suppressor. Most cases of multiple endocrine neoplasia type 1 are inherited in an autosomal dominant pattern.
MEN type 2
MEN type 2/type 2a
MEN syndrome types 2 and 3 have their basis in molecular genetics. Individuals can be tested for this genetic disorder reliably even when asymptomatic. The mutation is in the RET proto-oncogene. Most cases of multiple endocrine neoplasia types 2 and 3 are inherited in an autosomal dominant pattern.
Type 2 is also known as Sipple syndrome (after the American Dr John H. Sipple, who described it in 1961)[1] and used to be called type 2A:
- Medullary carcinoma of the thyroid which is associated with increased calcitonin secretion. A test for elevated calcitonin should be done after pentagastrin injection and/or calcium infusion, to ensure that all affected patients are detected.
- Pheochromocytoma
- Parathyroid hyperplasia/tumour causing hyperparathyroidism.
MEN type 3/type 2b
This syndrome has no eponym; it was described by Schimke et al in 1968.[1] Originally thought to be a third MEN, then considered a variant of II (especially after linkage to RET was confirmed), it is now considered its own syndrome.
- Pheochromocytoma
- Medullary carcinoma of thyroid which is associated with increased calcitonin secretion. A test for elevated calcitonin should be done after pentagastrin injection and/or calcium infusion, to ensure that all affected patients are detected.
- Mucosal neuromas which are usually situated in the gastrointestinal tract.
- Marfanoid habitus
References
External links
- Endocrine and Metabolic Diseases Information Service
- The Association for Multiple Endocrine Neoplasia Disorders (AMEND)
- Multiple Endocrine Neoplasia type 2 (MEN2 RET database)
de:Multiple endokrine Neoplasie it:Neoplasie multiendocrinesv:Multipla hormonella tumörer
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
